Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt small index

HCC: early-phase trial registry

9 of 14 indexed HCC trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,230 of 28,707 conditions by registered trial count.

14 US clinical trials · 9 currently recruiting · #1,230 of 28,707 conditions by registered trial count

HCC: 14 US clinical trials tracked, 9 recruiting.

HCC is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Geneos Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition hcc

OPEN 9 | RECR 64% | LATE 1 | EARLY 8 | RANK #1230 | SPON 1

Nearest open-share peer: Cardiac Rehabilitation (64% recruiting · 14 trials)

HCC (this)64%Acute Respiratory Failure35.7%Adherence, Medication35.7%Acromegaly28.6%Abscess7.1%
Open-enrollment share among volume-matched conditions near HCC

HCC lists 9 open slots (64% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for HCC on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. HCC is recruiting above its size-band peers.

    9 of 14 indexed trials (64.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of HCC trials is spread across many organizations.

    Geneos Therapeutics accounts for 1 of 14 trials (7.1%). 14 distinct sponsors appear on at least one study for this condition label.

  3. Most HCC trials plan to enrol fewer than 100 people.

    Median target enrolment is 70 among the 14 trials that report a genuine target (sentinel values excluded). 9 of those (64.3%) plan for fewer than 100 participants.

  4. HCC research is mostly interventional.

    12 interventional and 2 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 25Phase 41

Open and recent trials

14 total, page 1 of 1

RECRUITING 1,200 participants

Multi-analyte Blood Test Clinical Trial

Helio Genomics

NCT05199259

RECRUITING NA 600 participants

CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules

University of Texas Southwestern Medical Center

NCT06184152

RECRUITING Phase 4 220 participants

HOPE Against Cancer Recurrence in HCC

Philipp Dutkowski

NCT06717919

RECRUITING 104 participants

Optimizing Y90 Therapy for Radiation Lobectomy

Northwestern University

NCT04390724

RECRUITING Phase 1 70 participants

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC

RayzeBio

NCT06726161

RECRUITING Phase 2 62 participants

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

Stanford University

NCT07223307

RECRUITING NA 40 participants

Effect of the HCC Liver-Link Intervention

Indiana University

NCT06728293

RECRUITING Phase 2 35 participants

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

University of California, Irvine

NCT04472767

RECRUITING Phase 2 30 participants

Y-90 Treatment Response Using Transarterial Radioembolization

Thomas Jefferson University

NCT07145801

ACTIVE NOT RECRUITING Phase 1 36 participants

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC

Geneos Therapeutics

NCT04251117

COMPLETED Phase 1 114 participants

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Kyowa Kirin

NCT02705105

COMPLETED NA 84 participants

Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)

Icahn School of Medicine at Mount Sinai

NCT01871545

COMPLETED Phase 2 23 participants

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT01356628

COMPLETED Phase 2 3 participants

Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization

National Institutes of Health Clinical Center (CC)

NCT02471313

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 5
Phase 4 1

Named interventions

Most-linked intervention names on HCC records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PD-0332991 Drug
1 trials
Mogamulizumab + Nivolumab Biological
1 trials
[18F] Fmiso Drug
1 trials
CELLECTRA®2000 EP Device Device
1 trials
GNOS-PV02 Biological
1 trials
INO-9012 Biological
1 trials
aMRI imaging Diagnostic test
1 trials
CEUS imaging Diagnostic test
1 trials

US sites by state

Facility locations filed on HCC trials. A trial with sites in several states counts in each.

Maryland 5 trials
California 4 trials
Texas 3 trials
Pennsylvania 3 trials
New York 3 trials
Michigan 3 trials
Ohio 2 trials
Illinois 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this HCC page

14 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HCC condition card totals 14 registered trials; most-linked intervention PD-0332991; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.